Human butyrylcholinesterase knock-out equivalent:Potential to assess role in Alzheimer’s disease
Abstract
Butyrylcholinesterase (BChE) is an enzyme which
has been shown to be involved in the pathogenesis, treatment and prognosis of Alzheimer’s
disease. In its current form, however, evidence
is equivocal with all of the associations. Variant
forms of the protein exist, where the enzymatic
function is lost to varying degrees. We performed
in silico evaluation of these variants. Bioinformatics and molecular modeling, based on data
from ESTHER database and Protein Data Bank
(RCSB), were used for in silico predictions of the
structures of the silent variants that involve a
single amino acid change. Variants with loss of
enzyme activity were evaluated for structural
changes near the active site and the thermodynamic stability of the variants was estimated.
The results indicated that the loss of activity of
the variants can, in most cases, be attributed to
structural changes in the active site or to lower
thermodynamic stability. Our results showed
that the loss of enzyme activity may be due to
changes in the active site, oligomerization or
loss of structural stability. Individuals with loss
of function mutation of BChE can be studied and
followed up for their proneness or resistance to
cognitive decline with aging.